A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C
Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental
status, mottled and cool extremities, and delayed capillary refill, as well as signs of
congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to
organs) which frequently require support with rescue therapies including inotropes,
vasopressors, or mechanical devices.
Windtree Therapeutics, Inc. has been studying istaroxime, which has the potential to treat
patients in this condition without some of the disadvantages of existing therapies being used
to treat patients with acute heart failure and CS.
Participants enrolled in this trial will receive standard of care (SoC) therapy for heart
failure and CS. Additionally, half of the participants will be randomly chosen to receive
istaroxime. Istaroxime has the potential to increase blood pressure and improve cardiac
function.